Uc irvine fibrous histiocytoma skin’s lung cancer clinical trials — orange county, ca

This clinical trial studies nivolumab and ipilimumab in treating patients fibrous histiocytoma skin with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow fibrous histiocytoma skin and spread. This trial enrolls participants for the following cohorts based on fibrous histiocytoma skin condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer [NPC], and squamous cell carcinoma of the head and neck [SCCHN]) B) adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx. 2. Epithelial tumors of major salivary glands 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma 9. Intrahepatic cholangiocarcinoma 10. Extrahepatic cholangiocarcinoma and bile duct tumors 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in fibrous histiocytoma skin situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma. 13. Non-epithelial tumors of the ovary: A) germ cell tumor of ovary B) mullerian mixed tumor and adenosarcoma 14. Trophoblastic tumor: A) choriocarcinoma 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder 16. Cell tumor of the testes and extragonadal germ tumors: A) seminoma and testicular sex cord cancer B) non seminomatous tumor C) teratoma with malignant transformation 17. Epithelial tumors of penis – squamous adenocarcinoma cell carcinoma with variants of penis 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) 21. Odontogenic malignant tumors 22. Endocrine carcinoma of pancreas and digestive tract 23. Neuroendocrine carcinoma including carcinoid of the lung 24. Pheochromocytoma, malignant 25. Paraganglioma 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors 29. Malignant giant cell tumors 30. Chordoma 31. Adrenal cortical tumors 32. Tumor of unknown primary (cancer of unknown primary; cup) 33. Not otherwise categorized (NOC) rare tumors [to obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.Org] 34. Adenoid cystic carcinoma 35. Vulvar cancer 36. MetaPLASTIC carcinoma (of the breast) 37. Gastrointestinal stromal tumor (GIST)

The purpose of this study is to evaluate the efficacy fibrous histiocytoma skin and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of fibrous histiocytoma skin tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib [TAGRISSO®] failure) with T790M-negative mutation tumors, 2) T790M-positive mutation tumors with prior exposure to osimertinib, and 3) first-line osimertinib failure regardless of T790M mutation status. The primary study hypotheses are that the combination of pembrolizumab fibrous histiocytoma skin plus chemotherapy has superior efficacy compared to saline placebo plus fibrous histiocytoma skin chemotherapy in terms of: 1) progression-free survival (PFS) per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) based on blinded independent central review, and 2) overall survival (OS). This study will be considered to have met its success fibrous histiocytoma skin criteria if the combination of pembrolizumab plus chemotherapy is superior fibrous histiocytoma skin to saline placebo plus chemotherapy in terms of PFS or fibrous histiocytoma skin OS.

This open-label, multicenter study will assess the safety, tolerability, and pharmacokinetics of intravenous (IV) dosing of atezolizumab in combination with oral erlotinib or alectinib fibrous histiocytoma skin in participants with NSCLC. This study has two stages. In the erlotinib group, the combination treatment will be given to participants with epidermal fibrous histiocytoma skin growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-treatment-naive, advanced (nonresectable) NSCLC in a safety-evaluation stage and to participants with previously untreated EGFR mutation-positive, advanced NSCLC in an expansion stage (stage 2). In the alectinib group, for both the safety-evaluation and expansion stages (stages 1 and 2), the combination will be given to participants who are treatment-naive with anaplastic lymphoma kinase (ALK)-positive advanced NSCLC. In stage 1, erlotinib will be given at a starting dose of 150 fibrous histiocytoma skin milligrams (mg) by mouth (PO) once daily (QD) and the starting dose of alectinib will be 600 mg fibrous histiocytoma skin twice daily (BID), for 28 consecutive days during cycle 1 and on days fibrous histiocytoma skin 1 through 21 of each cycle thereafter. The starting dose of atezolizumab will be 1200 mg, administered every 3 weeks (q3w) starting on day 8 of cycle 1. If the starting regimen for a combination treatment is not fibrous histiocytoma skin tolerated, alternative doses and/or schedules of erlotinib and atezolizumab or alectinib and atezolizumab fibrous histiocytoma skin may be tested to determine potential recommended phase 2 dose fibrous histiocytoma skin (RP2D) for that combination treatment. In stage 2, a potential RP2D and schedule for each combination treatment will fibrous histiocytoma skin be investigated in an expansion cohort. For both stages, continuation of treatment beyond cycle 1 will be at the fibrous histiocytoma skin discretion of the treating investigator. Study treatment will be discontinued in participants who experience disease fibrous histiocytoma skin progression or unacceptable toxicity, are not compliant with the study protocol, or, in their opinion or in the opinion of the investigator, are not benefiting from study treatment. However, in the absence of unacceptable toxicity, participants with second-line or greater NSCLC who are still receiving atezolizumab at fibrous histiocytoma skin the time of radiographic disease progression may be permitted to fibrous histiocytoma skin continue study treatment.